**SUPPLEMENTAL INFORMATION**

**Analysis for Anakinra therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence**

**Kathryn Pillai, Joshua Pillai, Jun Ling\***

\*Correspondence should be addressed to J.L. (jun.ling@cusm.edu)

**This PDF includes:**

Supplementary Table 1

Supplementary Table 2

Supplementary Table 3

**Supplementary Table 1. Hemoglobin results from Anakinra therapy (*n* = 5).**

| **Pre-Treatment Hemoglobin (g/dL)** | **Post-Treatment Hemoglobin (g/dL)** |
| --- | --- |
| 9.3 | 11.4 |
| 12.5 | 12.7 |
| 7.6 | 13.4 |
| 9.4 | 13.3 |
| 9.2 | 13.1 |

**Supplementary Table 2. Erythrocyte Sedimentation Rate results from Anakinra therapy (*n* = 8).**

| **Pre-Treatment Erythrocyte Sedimentation Rate (mm/h)** | **Post-Treatment Erythrocyte Sedimentation Rate (mm/h)** |
| --- | --- |
| 113 | 17 |
| 26 | 5 |
| 57 | 10 |
| 56 | 0.83 |
| 51 | 15 |
| 69 | 2 |
| 58 | 32 |
| 115 | 36 |

**Supplementary Table 3. C-Reactive Protein results from Anakinra therapy (*n* = 7).**

| **Pre-Treatment C-Reactive Protein (mg/L)** | **Post-Treatment C-Reactive Protein (mg/L)** |
| --- | --- |
| 110.7 | 4.2 |
| 112 | 25 |
| 192.5 | 10 |
| 114 | 1.3 |
| 32 | 0.5 |
| 300 | 0 |
| 134 | 6.1 |